Develop a noncompetitive monoclonal anti-CD25
Ended Awarded Last action
- Contract number
- 75N91020F00034
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,275,555
Award facts
- Contract value 100% obligated
- $1,275,555.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $601,850 | |
| Exercise an Option | $84,579 | |
| Original award | $589,126 |
About this award
Leidos Biomedical Research Inc., a Federally Funded Research and Development Center (FFRDC) contractor and subsidiary of Leidos Holdings, Inc., was awarded a $1.28 million delivery order contract by the National Cancer Institute on September 25, 2020, to develop a noncompetitive monoclonal anti-CD25 therapeutic agent. The contract, which operates under a cost-plus-fixed-fee pricing model with no small business set-aside designation, will be performed at the Frederick National Laboratory for Cancer Research in Frederick, Maryland, and is scheduled for completion by June 30, 2026. This delivery order represents the type of specialized biomedical research and therapeutic development work that Leidos Biomedical Research Inc. routinely performs as an FFRDC supporting the National Cancer Institute and the National Institutes of Health.
The monoclonal anti-CD25 project aligns with the National Cancer Institute's broader mission to support cancer research and therapeutic innovation. Leidos Biomedical Research Inc. brings substantial experience in immunological research, gene therapy development, and manufacturing therapeutic agents through its extensive portfolio of federal contracts. The Frederick facility serves as a critical hub for the company's collaborative research efforts with federal agencies and academic institutions, positioning it well to manage the technical and operational requirements of developing targeted immunotherapy candidates for cancer treatment applications.
Quick answers
Who was awarded contract 75N91020F00034?
75N91020F00034 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 25, 2020.
How much is contract 75N91020F00034 worth?
The government has obligated $1,275,555 on 75N91020F00034.
Is contract 75N91020F00034 an order under another contract?
Yes. 75N91020F00034 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91020F00034 competed?
The extent of competition for 75N91020F00034 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award